Par Pharmaceutical Companies Reports First Quarter 2012 Results - MarketWatch (press release)
Updated NewsPar Pharmaceutical Companies Reports First Quarter 2012 ResultsMarketWatch (press release)Metoprolol: For the quarter ended March 31, 2012, net sales of metoprolol succinate were $61.
FDA Warns About More Hospira Syringes - MedPage Today
MedPage TodayFDA Warns About More Hospira SyringesMedPage TodayDrugs named in the announcement included meperidine (Demerol), diazepam, fentanyl citrate, ketorolac, labetalol, lorazepam, metoprolol, midazolam, naloxone, ondansetron, sodium chloride, and two types of heparin.
Sun Pharma rating upped to overweight, target Rs. 670 - Financial Express
Sun Pharma rating upped to overweight, target Rs.
Contrary to popular belief, beta-blockers don't prevent colorectal cancer - Los Angeles Times
Contrary to popular belief, beta-blockers don't prevent colorectal cancerLos Angeles TimesAmong the best known are atenolol (Tenormin), bisoprolol (Zebeta), metoprolol (Lopresor or Toprol) and carvedilol (Coreg).
Shoot Better Than Par With This Cheap Drug Stock - Forbes
Shoot Better Than Par With This Cheap Drug StockForbesSales of its biggest product, Metoprolol, which is the authorized generic for all strengths of AstraZeneca's Toprol XL, rose 9.